| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Graduate School of Medical and Dental Sciences, Course for Biological Functions and Medical Control, Department of Homeostatic Regulation and Development, Division of Respiratory Medicine, Niigata University, Niigata, Japan; and
Bioscience Medical Center, Niigata University Medical and Dental Hospital, Niigata, Japan
The peripheral tolerance mechanism prevents effective antitumor immunity, even though tumor cells possess recognizable tumor-associated Ags. Recently, it has been elucidated that regulatory T cells (Treg) play a critical role in maintaining not only self-tolerance, but also tolerance of tumor cells. However, because the Treg that maintain self-tolerance arise naturally in the thymus and are thought to be anergic in peripheral, it is still unclear where and when Treg for tumor cells are generated. In this study we analyze tumor-draining lymph nodes (LNs) and demonstrate that both antitumor effector T cells and Treg capable of abrogating the antitumor reactivity of the effector T cells are primed in the same LNs during tumor progression. The regulatory activity generated in tumor-draining LNs exclusively belonged to the CD4+ T cell subpopulation that expresses both CD25 and a high level of CD62L. Forkhead/winged helix transcription factor gene expression was detected only in the CD62LhighCD4+CD25+ T cells. CD62LhighCD4+CD25+ Treg and CD62LlowCD4+CD25+ T cells, which possess effector T cell functions, had comparable expression of LFA-1, VLA-4, CTLA-4, lymphocyte activation gene-3, and glucocorticoid-induced TNFR. Thus, only CD62L expression could distinguish regulatory CD4+CD25+ cells from effector CD4+CD25+ cells in draining LNs as a surface marker. The Treg generated in tumor-draining LNs possess the same functional properties as the Treg that arise naturally in the thymus but recognize tumor-associated Ag. CD62LhighCD4+CD25+ Treg contained a subpopulation that expressed CD86. Blocking experiments revealed that ligation of CTLA-4 on effector T cells by CD86 on Treg plays a pivotal role in regulating CD4+ effector T cells.
This article has been cited by other articles:
|
|
 |
|
  T. Fujita, K. Teramoto, Y. Ozaki, J. Hanaoka, N. Tezuka, Y. Itoh, T. Asai, S. Fujino, K. Kontani, and K. Ogasawara Inhibition of Transforming Growth Factor-{beta}-Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell Types Cancer Res., June 15, 2009; 69(12): 5142 - 5150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, J. H. Kim, L. D. Falo Jr., and Z. You Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity J. Immunol., May 15, 2009; 182(10): 6160 - 6167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, et al. Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage Clin. Cancer Res., November 1, 2008; 14(21): 6770 - 6779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Piconese, B. Valzasina, and M. P. Colombo OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection J. Exp. Med., April 14, 2008; 205(4): 825 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Degl'Innocenti, M. Grioni, G. Capuano, E. Jachetti, M. Freschi, M. T.S. Bertilaccio, R. Hess-Michelini, C. Doglioni, and M. Bellone Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells Cancer Res., January 1, 2008; 68(1): 292 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens PNAS, July 17, 2007; 104(29): 12087 - 12092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Gabriel and E. C. Lattime Anti-CTL-Associated Antigen 4: Are Regulatory T Cells a Target? Clin. Cancer Res., February 1, 2007; 13(3): 785 - 788. [Full Text] [PDF]
|
|
|
|
|
|
D. O'Mahony, J. C. Morris, C. Quinn, W. Gao, W. H. Wilson, B. Gause, S. Pittaluga, S. Neelapu, M. Brown, T. A. Fleisher, et al. A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy Clin. Cancer Res., February 1, 2007; 13(3): 958 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cosentino, A. M. Fietta, M. Ferrari, E. Rasini, R. Bombelli, E. Carcano, F. Saporiti, F. Meloni, F. Marino, and S. Lecchini Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop Blood, January 15, 2007; 109(2): 632 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Venturi, R. M. Conway, D. A. Steeber, and T. F. Tedder CD25+CD4+ Regulatory T Cell Migration Requires L-Selectin Expression: L-Selectin Transcriptional Regulation Balances Constitutive Receptor Turnover J. Immunol., January 1, 2007; 178(1): 291 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hiraoka, K. Onozato, T. Kosuge, and S. Hirohashi Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions. Clin. Cancer Res., September 15, 2006; 12(18): 5423 - 5434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Beyer and J. L. Schultze Regulatory T cells in cancer Blood, August 1, 2006; 108(3): 804 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Dejaco, C. Duftner, and M. Schirmer Induction of Tolerance in Autoimmune Diseases Rather Than Cure of Cancer by Interleukin-2 Therapy J. Clin. Oncol., July 10, 2006; 24(20): e34 - e34. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
